Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431930 | 0.86 | TSHR (0.52) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL1639686 | 0.82 | CYP3A4 (0.32) | TSHR | |
| SCHEMBL434384 | 0.81 | TSHR (0.34) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL9252191 | 0.78 | TSHR (0.41) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL14590764 | 0.73 | — | — | |
| SCHEMBL1146478 | 0.73 | ALDH1A1 (0.36) | MEN1THRBKMT2ATSHRALDH1A1 | |
| SCHEMBL31079405 | 0.73 | THRB (0.40) | THRB | |
| SCHEMBL13319641 | 0.72 | ALDH1A1 (0.50) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL6227646 | 0.72 | THRB (0.44) | THRB | |
| SCHEMBL7753817 | 0.72 | THRB (0.44) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853325-B2 | Water-soluble polymer alkanals | NEKTAR THERAPEUTICS (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120065429-A1 | WATER-SOLUBLE POLYMER ALKANALS | NEKTAR THERAPEUTICS (US) | 2012-03-15 | — | — | US | disclosed |
| US-8076412-B2 | Water-soluble polymer alkanals | NEKTAR THERAPEUTICS (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110034737-A1 | Water-Soluble Polymer Alkanals | NEKTAR THERAPEUTICS (US) | 2011-02-10 | — | — | US | disclosed |
| US-7838595-B2 | high purity; storage stability; electrophilically activated polymer derivatives with aldehyde functionality for conjugating to biologically active molecules; drug-polymer conjugate; | NEKTAR THERAPEUTICS (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090234070-A1 | high purity; storage stability; electrophilically activated polymer derivatives with aldehyde functionality for conjugating to biologically active molecules; drug-polymer conjugate; | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| US-7511094-B2 | 2-methylbutyraldehyde diethyl acetal end capped polyoxyethylene glycol; polyalkylene oxide, polyivnylpyrrolidone, polyvinyl alcohol, polyoxazoline etc. endcapped with polyetherpolyamine copolymers or oligomers covalently attached to diacetal tetramethylene group | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7157546-B2 | Polyoxyethylene glycol; purity, storage stability | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065429-A1 | WATER-SOLUBLE POLYMER ALKANALS | ALK, ALKBH3, AQP1 | MEN1 4247/4885THRB 4877/4885HTT 837/4885 |
| US-20110034737-A1 | Water-Soluble Polymer Alkanals | ALK, ALKBH3, AQP1 | MEN1 4247/4885THRB 4877/4885HTT 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.